Shanghai Pulmonary Hospital, Shanghai, China: Adenocarcinoma of Lung trials

The registry lists 10 Adenocarcinoma of Lung studies with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 2 4Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCTNot yet recruitingNCT07169903Phase 3
• Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaRecruitingNCT06528847Phase 2
• WSI Based DL for Diagnosing the IASLC Grading System of Lung AdenocarcinomaRecruitingNCT05925764
• Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmRecruitingNCT05838053
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaRecruitingNCT05503667Phase 2
• Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmRecruitingNCT04937283Not applicable
• Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%RecruitingNCT03351842Phase 2
• Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung AdenocarcinomaStatus unknownNCT05736991
• Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary NodulesStatus unknownNCT04554875
• Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaCompletedNCT04201756Phase 2